Third Harmonic Bio
fund manager
sector
Healthcare
geography
North America
Vintages
status
Portfolio
category
#Innovative

Third Harmonic Bio

Co-invested company
Third Harmonic Bio is a pharmaceutical company that develops a treatment for allergies and severe inflammation.
Photo of two scientists representing Third Harmonic Bio, part of the Private Equity manager's portfolio. General Atlantic

Key figures for Third Harmonic Bio

373 M$
market capitalization in 2024
2019
year established
Data at
4/10/24
*Source: Public data from company websites and social networks. For the most up-to-date information, we invite our investors to consult the reports available in their own space.

About Third Harmonic Bio

Third Harmonic Bio is a biopharmaceutical company focused on driving the next wave of drugs for inflammatory diseases through the development of novel, highly selective small molecule inhibitors of KIT, a cell surface receptor that acts as the master regulator of mast cell function and survival.

Preliminary clinical studies demonstrate that KIT inhibition has the potential to revolutionize the treatment of a wide range of mast cell-mediated inflammatory diseases, and that an oral, titratable intracellular small molecule inhibitor could offer the optimal therapeutic profile against this target.

Third Harmonic Bio's lead product candidate, THB335, is a titratable, oral, intracellular small molecule inhibitor scheduled to enter clinical trials in the first half of 2024.

In the same sector as Third Harmonic Bio

Company videos
No items found.
Discover our exclusive services
General Atlantic
Odyssey 2021
Odyssey 2021
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio
Portfolio